Skip to main
ANTX
ANTX logo

ANTX Stock Forecast & Price Target

ANTX Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 0%
Buy 67%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

AN2 Therapeutics Inc. is positioned favorably in the biopharmaceutical market due to the promising safety and tolerability profile of its lead candidate, epetraborole, which demonstrated mild and reversible reductions in hemoglobin during Phase 2 trials. The drug shows potential for significant clinical impact on quality of life for patients suffering from non-tuberculous mycobacterial (NTM) infections, particularly with its ability to reduce cough frequency and intensity, a common debilitating symptom in these patients. Additionally, the company’s positive outlook is bolstered by strong pre-clinical data indicating epetraborole's effectiveness against more challenging NTM strains, suggesting a potential expansion of its therapeutic application in treating these serious infections.

Bears say

AN2 Therapeutics Inc faces significant challenges that contribute to a negative outlook on its stock, primarily due to disappointing clinical results from its lead candidate, epetraborole, and a historical pattern of financial losses without a clear path to profitability. The company is also exposed to considerable risks associated with its development pipeline, including potential failures to meet efficacy and safety endpoints, which could jeopardize regulatory approval and commercialization efforts. Additionally, AN2 faces uncertainties related to market conditions, emerging competition, and the possible impact of litigation on its market exclusivity, all of which heighten the financial risks associated with its investments in novel therapeutics.

ANTX has been analyzed by 6 analysts, with a consensus rating of Buy. 0% of analysts recommend a Strong Buy, 67% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AN2 Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AN2 Therapeutics Inc (ANTX) Forecast

Analysts have given ANTX a Buy based on their latest research and market trends.

According to 6 analysts, ANTX has a Buy consensus rating as of Aug 2, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10.83, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10.83, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AN2 Therapeutics Inc (ANTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.